Free Trial

hVIVO (LON:HVO) Shares Up 12.3% - Time to Buy?

hVIVO logo with Medical background

Key Points

  • hVIVO's stock price increased by 12.3% during mid-day trading, reaching a high of GBX 8 ($0.11) before closing at GBX 7.75 ($0.10).
  • Recent analyst reports showed a buy rating from Shore Capital with a reduced price target of GBX 25 and an add rating from Peel Hunt with a price objective of GBX 21.
  • hVIVO reported a quarterly earnings per share of GBX (0.29) with a net margin of 25.96% and projects an EPS of 1.549 for the current year.
  • Five stocks to consider instead of hVIVO.

hVIVO plc (LON:HVO - Get Free Report)'s stock price shot up 12.3% during mid-day trading on Monday . The company traded as high as GBX 8 ($0.11) and last traded at GBX 7.75 ($0.10). 7,239,963 shares changed hands during trading, an increase of 145% from the average session volume of 2,958,062 shares. The stock had previously closed at GBX 6.90 ($0.09).

Analyst Ratings Changes

HVO has been the subject of several recent research reports. Shore Capital cut their price target on hVIVO from GBX 35 to GBX 25 and set a "buy" rating for the company in a research note on Tuesday, September 23rd. Peel Hunt reaffirmed an "add" rating and issued a GBX 21 price objective on shares of hVIVO in a report on Tuesday, July 29th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, hVIVO presently has an average rating of "Buy" and a consensus price target of GBX 23.

Get Our Latest Stock Report on hVIVO

hVIVO Trading Up 12.3%

The firm's 50-day simple moving average is GBX 9.27 and its 200 day simple moving average is GBX 12. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The firm has a market capitalization of £53.23 million, a price-to-earnings ratio of 1,005.97 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last issued its quarterly earnings results on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Equities analysts expect that hVIVO plc will post 1.5492958 earnings per share for the current year.

hVIVO Company Profile

(Get Free Report)

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in hVIVO Right Now?

Before you consider hVIVO, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.

While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.